Abstract
Introduction
A recombinant tissue plasminogen activator (rt-PA) was approved by the Food and Drug Administration (FDA) based on the results of the National Institute of Neurological Disorders and Stroke (NINDS) trial in 1996 for ischaemic stroke treatment [1] . Tissue type plasminogen activator is more clot specific which means that it promotes the conversion of plasminogen to plasmin only when bound to fibrin in a thrombus [2] . Intravenous thrombolysis with rt-PA improves functional neurological outcome and reduces mortality in acute ischaemic stroke [3] . The proportion of patients who benefit from thrombolysis by at least one point on the modified Rankin Scale (mRS) has been calculated to 32% [4] . It was shown that 40.6% of stroke patients treated with rt-PA had a 3-month mRS score ≤ 1 [5] . A beneficial effect is also observed after 1 year, with a disability reduction of 30%. Rt-PA decreases the relative risk of death or disability after 3 months by 13%. The recommended therapeutic window is 4.5 h after stroke onset [6] [7] [8] .
There are prognostic factors of thrombolytic treatment in stroke [9] . The early neurological improvement may also be an important factor indicating the outcome. There have been diverse definitions used to describe the rapid recovery. In one study the rapid neurological recovery was defined as an improvement of at least 50% within 24 h measured by the National Institute of Health Stroke Scale (NIHSS) and was correlated with favourable outcome at 3 months [10] . Other authors defined an early neurological improvement as the NIHSS score between 0 and 4 at 24 h. Patients with worsening in neurological deficit (i.e. increase in NIHSS ≥ 1 point) had worse outcome at 3 months [11] . The quartiles of 24-hour NIHSS score strongly predict the 3-12-month outcome and quality of life index [12] . In a recent study very early improvement was analysed defined as the difference between baseline and 2-hour NIHSS score (very early post-randomisation improvement -VEPRIM) in relation to 3-month outcome, and decreased risk of death and symptomatic intracerebral haemorrhage (SICH) [13] . The neurological improvement during the first 24 h after thrombolysis was a strong predictor of favourable outcome at 3 months also in other studies [14] [15] [16] . Moreover, an improvement in NIHSS scale observed at 15 and 30 min after the rt-PA infusion predicts outcome at 3 months [17] . Other authors defined improvement as the NIHSS score improvement by 40% from baseline and compared patients at 1 h after thrombolysis (very early neurological improvement -VENI) and at 24 h (early neurological improvement -ENI) [18] . Early neurological improvement was also defined as eight or more points in NIHSS 24 h after thrombolysis while neurological improvement was defined as an improvement of at least eight points at discharge (compared with baseline) [19] .
As presented above, different settings are used to assess early improvement. In our study we assessed early neurological improvement 24 h after rt-PA treatment, concentrating on the in-hospital factors that can potentially be detected and effectively treated, because they affect the long-term outcome.
Aim of the research
The aim of the study was to establish unfavourable prognostic factors influencing the in-hospital outcome in stroke patients treated with rt-PA.
Material and methods
A retrospective analysis of 245 consecutive ischaemic stroke patients treated intravenously with rt-PA was conducted. Subjects were hospitalised in the Department of Neurology.
The outcome was analysed in two groups 24 h after rt-PA treatment, depending on the NIHSS score: group I consisted of 105 patients with the improvement in NIHSS ≥ 2 points 24 h after intravenous rt-PA administration, and group II comprised of the rest of the patients (140 individuals): with no improvement, improvement < 2 points, or with deterioration.
The NIHSS score was assessed initially before treatment (NIHSS I) and 24 h after (NIHSS II) according to the definition [20] . The initial systolic (SBP) and diastolic blood pressure (DBP) were measured just after admission to the hospital.
The rest of the analysed factors were obtained from the history and medical records or diagnosed during hospitalisation, including: hypertension, coronary heart disease, myocardial infarction, atrial fibrillation, type 2 diabetes mellitus, smoking, past stroke/ transient ischaemic attack (TIA), significant stenosis of internal carotid artery (≥ 70%), previous use of antiplatelet or oral anticoagulant treatment, previous antihypertensives, occupation (blue and white collar), age, sex, body mass index, initial body temperature, serum C-reactive protein (CRP), white blood cells count, fibrinogen, and haematocrit. Ultrasonography of the carotid arteries was performed with a GE LOGIQ Book XP camera, linear head 7.5 MHz, and Esaote MyLab Twice linear head 7.5 MHz. Particular definitions are given elsewhere [21] . The date and time of admission to the hospital with special consideration to the weekend were also taken into account. Based on initial brain computed tomography (CT) the presence of previous ischaemic changes and acute ischaemic damage were assessed. The therapeutic window was the period between the onset of the symptoms and the time the rt-PA administration was started.
The initial factors (NIHSS, body temperature, blood pressure, brain CT) mean those assessed on the Emergency Unit directly before admission to the Neurology Department. 
Statistical analysis
Statistical analysis was performed using Statistica 10 software. Because the distributions of most variables were significantly different from normal (Shapiro-Wilk test was used to assess whether data obtained were normally distributed), the results were calculated with the use of tests: c 2 test, Kruskal-Wallis ANOVA, Mann-Whitney U-test, univariate, and multivariate analyses. The level of significance was adopted as p < 0.05.
Results
Comparison of prognostic factors between group I and II with reference to the outcome 24 h after rt-PA administration are presented in Tables 1 and 2 . Patients from group II more often had hypertension, presence of old ischaemic changes in brain CT, greater baseline neurological deficit, and longer therapeutic window. Both uni-and multivariate analysis confirmed these results with statistically significant values (Tables 3 and 4) .
Discussion
The early effectiveness of intravenous rt-PA administration in stroke patients was analysed in relation to the NIHSS score 24 h after administration. The outcome on the second day was assessed as an improvement of NIHSS ≥ 2 points versus other cases. The border of > 1 point was established to avoid subjective, small intraobserver differences of the physical examination.
In our study the mean onset-to-treatment time was statistically longer and connected with lesser improvement in NIHSS II assessments. It appeared to be an independent risk factor in uni-and multivariate analysis. In other publications it was also presented that the time from the onset of stroke to treatment was connected with a favourable outcome in mRS at day 90 [22] [23] [24] . These observations are consistent with the recommendations that every effort should be made to treat patients as early as possible after symptom onset [25] . Of note is that other authors showed no association between the therapeutic window and rapid neurological recovery defined as an improvement ≥ 50% in NIHSS score within the first 24 h after rt-PA treatment [10] .
Other authors established the factors that have an influence on bad outcomes measured in mRS at 3 months in VENI patients, i.e.: recent TIA, higher baseline NIHSSS, shorter onset-to-needle time, and less frequent pneumonia and malignant infarction [24] .
In our study the hypertension was connected with lower frequency of improvement in NIHSS II assessment and was found as an independent risk factor of worse prognosis. In the ECASS study hypertension was also a significant factor affecting the longterm outcome [22] . On the other hand, we observed that the initial values of blood pressure, irrespective of hypertension history, did not affect the outcome. Such a finding seems to be consistent with the recommendations indicating the benefit of maintaining the initial blood pressure at a higher level [6] . The role of blood pressure in thrombolytic treatment was also observed by other authors, which demonstrated that blood pressure variability was associated with greater diffusion-weighted magnetic resonance imaging lesion growth and worse clinical course in patients with stroke treated with rt-PA [16] . Higher initial values of SBP in patients with no history of hypertension were connected with increased risk of SICH secondary to thrombolysis [26] . Patients benefited from rt-PA in terms of no or negligible handicap after 90 days, without excess risk of death, with baseline SBP between 140 and 160 mm Hg or baseline DBP between 80 and 90 mm Hg [27] . In future studies the impact of blood pressure values and use of hypotensives in rt-PAtreated patients should be more precisely analysed. We analysed only the period of early hospital treatment, but our results may be used in predicting longterm outcome and potential intensification of treatment in terms of secondary prevention, because, as shown by other authors, rapid neurological recovery is correlated with favourable outcomes assessed by 3-month mRS [10, [14] [15] [16] . In another study the day-7/10 mRS was independently and strongly associated with day-90 mRS. The authors suggested that functioning after first week, supplemented by initial stroke severity and history information of congestive heart failure, may provide an early outcome guide useful for more intensive and efficient secondary prevention [28] . Disability and mortality at day 90 was also proven to be connected with baseline NIHSS score in other studies [7, 22] . We obtained similar results regarding baseline NIHSS score. In our patients a higher score was connected with a worse outcome and appeared to be an important predictor of worse prognosis, which is consistent with other studies [10, 23] . On the other hand, it was presented that VENI patients assessed 1 h after rt-PA have higher baseline NIHSS score [24] . Interestingly, lower baseline NIHSS was connected with early neurological deterioration [29] .
We showed that patients with the presence of old ischaemic changes in the initial brain CT were less likely to gain 24-hour neurological improvement. The role of such findings is not clear, but similar results were presented by other authors -the presence of radiological signs of previous stroke in baseline CT was connected with higher rate of death within 3 months of thrombolysis [7] . This is presumably connected with the presence of evident or clinically silent cerebrovascular disorders in such patients, similarly to the interpretation of white matter hyperintensities [30] . The role of white matter hyperintensities in rt-PA stroke treatment may be of interest in future analyses.
We showed that significant stenosis of the internal carotid artery did not affect the early outcome. Contrary to our results, a recent study comparing the effect of intravenous rt-PA with placebo within the 3-6-hour therapeutic window reported that most patients with ICA occlusion did not achieve good clinical outcomes, whether treated with rt-PA or placebo [31] . Internal carotid artery occlusion was independently associated with early neurological deterioration after rt-PA therapy [29] . This suggests that the presence of carotid artery stenosis is not an early prognostic factor in patients treated with rt-PA in opposition to the occlusion of carotid arteries.
We did not find diabetes to be a factor affecting the early outcome. As presented by other authors, higher blood glucose levels are connected with lower grade of early neurological improvement and even with higher risk of early deterioration after rt-PA treatment [10, 29] .
Our results indicate that age cannot be used as a prognostic factor of early improvement in thrombolytic treatment. This is inconsistent with other studies that indicated younger age as a significant predictor of good early and long-term outcome [7, 10, 32] .
The limitation of our study is the small sample size and the fact that the analysis was performed as a single-centre study.
Conclusions
There are factors affecting the grade of early neurological improvement assessed 24 h after rt-PA therapy, which should be taken into consideration in the acute phase treatment and secondary prevention of thrombolysed stroke patients. The group of patients that should be of special interest during the hospitalisation are those with hypertension, greater initial neurological deficit, longer onset-to-treatment time, and old ischaemic changes in initial brain CT. 
